Ivan Jambor

Ivan Jambor

Auto-generated profile, based on publicly available information

Ivan Jambor

University of Turku

Research Focus & Metrics

Academic Career Length

54Years (1973-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EKEsa Kähkönen
Esa Kähkönen
IJIvan Jambor
Ivan Jambor
JKJukka Kemppainen
Jukka Kemppainen
KLKaisa Lehtiö
Kaisa Lehtiö
TGTove J. Grönroos
Tove J. Grönroos
HMHeikki Minn
Heikki Minn
Purpose: A novel [68Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 peptide (BAY86-7548) having high affinity to bombesin receptor subtype II to detect primary and metastatic prostate carcinoma using positron emission tomography/computed tomography (PET/CT) was synthesized and evaluated for prostate cancer. Experimental Design: In this first human study with BAY86-7548, 14 men scheduled for radical prostatectomy (n = 11) or with biochemical recurrence after surgery or hormonal therapy (n = 3) were enrolled. The patients received an intravenous injection of BAY86-7548 followed by over 60-minute dynamic imaging of prostate gland (n = 10) and/or subsequent whole-body imaging (n = 14). The visual assessment of PET/CT images included evaluation of intraprostatic (12 subsextants) and pelvic nodal uptake of BAY86-7548 in 11 surgical patients and detection of potential metastatic foci in all patients. In patients with biochemical recurrence, results were compared with those of either [11C]-acetate (n = 2) or [18F]-fluoromethylcholine (n = 1) PET/CT. Results: We found a sensitivity, specificity, and accuracy of 88%, 81% and 83%, respectively, for detection of primary PCa and sensitivity of 70% for metastatic lymph nodes using histology as gold standard. BAY86-7548 correctly detected local recurrence in prostate bed and showed nodal relapse in accordance with [11C]-acetate PET/CT in 2 patients with biochemical relapse. In the third hormone refractory patient, BAY86-7548 failed to show multiple bone metastases evident on [18F]-fluoromethylcholine PET/CT. Conclusion: BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer. Clin Cancer Res; 19(19); 5434–43. ©2013 AACR.

2 April 2015 in Acta Oncologica
Verified
Journal Article
Closed access
IJIvan Jambor
Ivan Jambor
AKAnna Kuisma
Anna Kuisma
SRSusan Ramadan
Susan Ramadan
RHRiikka Huovinen
Riikka Huovinen
MSMinna Sandell
Minna Sandell
MSMarko Seppänen
Marko Seppänen
Detection of bone metastases in breast and prostate cancer patients remains a major clinical challenge. The aim of the current trial was to compare the diagnostic accuracy of (99m)Tc-hydroxymethane diphosphonate ((99m)Tc-HDP) planar bone scintigraphy (BS), (99m)Tc-HDP SPECT, (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/CT and whole body 1.5 Tesla magnetic resonance imaging (MRI), including diffusion weighted imaging, (wbMRI+DWI) for the detection of bone metastases in high risk breast and prostate cancer patients. Twenty-six breast and 27 prostate cancer patients at high risk of bone metastases underwent (99m)Tc-HDP BS, (99m)Tc-HDP SPECT, (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/CT and wbMRI+DWI. Five independent reviewers interpreted each individual modality without the knowledge of other imaging findings. The final metastatic status was based on the consensus reading, clinical and imaging follow-up (minimal and maximal follow-up time was 6, and 32 months, respectively). The bone findings were compared on patient-, region-, and lesion-level. (99m)Tc-HDP BS was false negative in four patients. In the region-based analysis, sensitivity values for (99m)Tc-HDP BS, (99m)Tc-HDP SPECT, (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/CT, and wbMRI+DWI were 62%, 74%, 85%, 93%, and 91%, respectively. The number of equivocal findings for (99m)Tc-HDP BS, (99m)Tc-HDP SPECT, (99m)Tc-HDP SPECT/CT, (18)F-NaF PET/CT and wbMRI+DWI was 50, 44, 5, 6, and 4, respectively. wbMRI+DWI showed similar diagnostic accuracy to (18)F-NaF PET/CT and outperformed (99m)Tc-HDP SPECT/CT, and (99m)Tc-HDP BS.

7 May 2018 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
RSRakesh Shiradkar
Rakesh Shiradkar
SGSoumya Ghose
Soumya Ghose
IJIvan Jambor
Ivan Jambor
PTPekka Taimen
Pekka Taimen
OEOtto Ettala
Otto Ettala
AMAnant Madabhushi
Anant Madabhushi

19 December 2016 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
SGShoshana B. Ginsburg
Shoshana B. Ginsburg
AAAhmad Algohary
Ahmad Algohary
SPShivani Pahwa
Shivani Pahwa
VGVikas Gulani
Vikas Gulani
LPLee Ponsky
Lee Ponsky
Anant MadabhushiAnant Madabhushi
Anant Madabhushi

22 February 2018 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
AAAhmad Algohary
Ahmad Algohary
SVSatish E Viswanath
Satish E Viswanath
RSRakesh Shiradkar
Rakesh Shiradkar
SGSoumya Ghose
Soumya Ghose
SPShivani Pahwa
Shivani Pahwa
AMAnant Madabhushi
Anant Madabhushi

5 April 2013 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Anne RoivainenAnne Roivainen
Anne Roivainen
EKEsa Kähkönen
Esa Kähkönen
PLPauliina Luoto
Pauliina Luoto
SBSandra Borkowski
Sandra Borkowski
BHBirte Hofmann
Birte Hofmann
HMHeikki Minn
Heikki Minn
This first-in-human study investigated the safety, tolerability, metabolism, pharmacokinetics, biodistribution, and radiation dosimetry of 68Ga-bombesin antagonist 68Ga-DOTA-4-amino-1-carboxymethylpiperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (BAY 86-7548). Methods: Five healthy men underwent dynamic whole-body PET/CT after an intravenous injection of BAY 86-7548 (138 ± 5 MBq). Besides total radioactivity, plasma samples were analyzed by radio–high-performance liquid chromatography for metabolism of the tracer. Dosimetry was calculated using the OLINDA/EXM software. Results: Three radioactive plasma metabolites were detected. The proportion of unchanged BAY 86-7548 decreased from 92% ± 9% at 1 min after injection to 19% ± 2% at 65 min. The organs with the highest absorbed doses were the urinary bladder wall (0.62 mSv/MBq) and the pancreas (0.51 mSv/MBq). The mean effective dose was 0.051 mSv/MBq. BAY 86-7548 was well tolerated by all subjects. Conclusion: Intravenously injected BAY 86-7548 is safe, and rapid metabolism is demonstrated. A 150-MBq injection of BAY 86-7548 results in an effective dose of 7.7 mSv, which could be reduced to 5.7 mSv with frequent bladder voids.